Pathologie als Gatekeeper

[1]  A. Warth,et al.  ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 cases , 2014, Histopathology.

[2]  A. Warth,et al.  Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. , 2014, Anticancer research.

[3]  Martin Vingron,et al.  Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids , 2014, Nature Communications.

[4]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[5]  Yong Soo Choi,et al.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Volker Endris,et al.  Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. , 2013, The Journal of molecular diagnostics : JMD.

[7]  G. Getz,et al.  A Genomics-Based Classification of Human Lung Tumors , 2013, Science Translational Medicine.

[8]  I. Petersen,et al.  Adenokarzinome der Lunge – die neue Klassifikation , 2013, Zentralblatt für Chirurgie – Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie.

[9]  I. Petersen,et al.  Association of small foci of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) with adenocarcinoma of the lung. , 2013, Pathology, research and practice.

[10]  A. Warth,et al.  EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype , 2013, European Respiratory Journal.

[11]  D. Maintz,et al.  Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. , 2013, Lung cancer.

[12]  G. Bepler,et al.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Weichert,et al.  Molekulare Diagnostik in der Pathologie , 2013, Deutsche Medizinische Wochenschrift.

[14]  J. Pignon,et al.  ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. , 2013, The New England journal of medicine.

[15]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Soria,et al.  ERCC1 and RRM1: ready for prime time? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Salgia,et al.  MET as a possible target for non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Edward S. Kim,et al.  Epidermal growth factor receptor inhibition in lung cancer: status 2012. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[21]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[22]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[23]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[24]  A. Warth,et al.  Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies , 2012, Virchows Archiv.

[25]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[26]  J. Roth,et al.  Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. , 2011, Clinical lung cancer.

[27]  E. Kwak.  The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. , 2011, The oncologist.

[28]  A. Warth,et al.  Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy , 2011, European Respiratory Journal.

[29]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Meyerson,et al.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.

[31]  I. Petersen,et al.  Gender and ploidy in cancer survival , 2011, Cellular Oncology.

[32]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  E. Stelow.  A Review of NUT Midline Carcinoma , 2011, Head and neck pathology.

[34]  Michael Thomas,et al.  Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  C. Obasaju,et al.  Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[37]  I. Petersen,et al.  EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC , 2010, Virchows Archiv.